

14868 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

treatment of obesity has been generally accepted by experts qualified by training and experience to make these judgements. Our data, confirmed by other investigators and resulting from separate investigations of amphetamine formulations and two related drugs can be summarized as follows:

1. Patients treated with amphetamines who complete the study requirements (weekly clinical visits, maintenance of the prescribed dosage intake, continued diligence during study periods ranging from 8 to 16 weeks) on the average will lose more weight than patients who are maintained on placebo medication during equivalent periods of time.
2. Weight loss in both placebo and treated groups are more notable when dietary plans are detailed and maximum caloric intakes are calculated for each patient on the basis of height and body build, in contrast to weight losses associated with less rigid programs involving non-specific dietary restrictions.
3. Fewer patients treated with placebo can maintain the personal motivation required to complete a weight reduction program, in comparison to patients treated with an amphetamine formulation or related product. There will be significantly more drop-outs in the placebo group prior to completion of the study requirements.